Neuraminidase reassortment and oseltamivir resistance in clade 2.3.4.4b A(H5N1) viruses circulating among Canadian poultry, 2024.

IF 8.4 2区医学 Q1 IMMUNOLOGY

Emerging Microbes & Infections Pub Date : 2025-12-01 Epub Date: 2025-03-11 DOI:10.1080/22221751.2025.2469643

Anthony V Signore, Tomy Joseph, Charlene Ranadheera, Cassidy N G Erdelyan, Tamiru N Alkie, Sugandha Raj, Lemarie Pama, Ifeoluwa Ayilara, Tamiko Hisanaga, Oliver Lung, Nathalie Bastien, Yohannes Berhane

引用次数: 0

Abstract

We report the detection of a clade 2.3.4.4b A(H5N1) reassortant virus with a neuraminidase surface protein derived from a North American lineage low-pathogenic avian influenza virus. This virus caused a widespread and ongoing outbreak across 45 poultry farms in British Columbia, Canada. Isolates from 8 farms reveal a mutation in the neuraminidase protein (H275Y) that is exceptionally rare among clade 2.3.4.4b viruses (present in 0.045% of publicly available clade 2.3.4.4b isolates). NA-H275Y is a well-known marker of resistance to the neuraminidase inhibitor oseltamivir. We demonstrate that this substitution maintains its resistance phenotype on the genetic background of H5N1 clade 2.3.4.4b viruses.

查看原文本刊更多论文

加拿大家禽中传播的2.3.4.4b A（H5N1）进化支神经氨酸酶重组和奥司他韦耐药性

我们报告了一种来自北美谱系低致病性禽流感病毒的神经氨酸酶表面蛋白的进化枝2.3.4.4b a （H5N1）重组病毒的检测。该病毒在加拿大不列颠哥伦比亚省的45个家禽养殖场引起了广泛和持续的爆发。来自8个农场的分离株显示神经氨酸酶蛋白（H275Y）突变，这在2.3.4.4b进化支病毒中极为罕见（在公开获得的2.3.4.4b进化支分离株中存在0.045%）。NA-H275Y是对神经氨酸酶抑制剂奥司他韦耐药的已知标记物。我们证明这种替代在H5N1分支2.3.4.4b病毒的遗传背景下保持了其抗性表型。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Emerging Microbes & Infections IMMUNOLOGY-MICROBIOLOGY

CiteScore

26.20

自引率

2.30%

发文量

276

审稿时长

20 weeks

期刊介绍： Emerging Microbes & Infections is a peer-reviewed, open-access journal dedicated to publishing research at the intersection of emerging immunology and microbiology viruses. The journal's mission is to share information on microbes and infections, particularly those gaining significance in both biological and clinical realms due to increased pathogenic frequency. Emerging Microbes & Infections is committed to bridging the scientific gap between developed and developing countries. This journal addresses topics of critical biological and clinical importance, including but not limited to: - Epidemic surveillance - Clinical manifestations - Diagnosis and management - Cellular and molecular pathogenesis - Innate and acquired immune responses between emerging microbes and their hosts - Drug discovery - Vaccine development research Emerging Microbes & Infections invites submissions of original research articles, review articles, letters, and commentaries, fostering a platform for the dissemination of impactful research in the field.